Neovascularization and tissue regeneration by endothelial progenitor cells in ischemic stroke

Endothelial progenitor cells (EPCs) are immature endothelial cells (ECs) capable of proliferating and differentiating into mature ECs. These progenitor cells migrate from bone marrow (BM) after vascular injury to ischemic areas, where they participate in the repair of injured endothelium and new blood vessel formation. EPCs also secrete a series of protective cytokines and growth factors that support cell survival and tissue regeneration. Thus, EPCs provide novel and promising potential therapies to treat vascular disease, including ischemic stroke. However, EPCs are tightly regulated during the process of vascular repair and regeneration by numerous endogenous cytokines that are associated closely with the therapeutic efficacy of the progenitor cells. The regenerative capacity of EPCs also is affected by a range of exogenous factors and drugs as well as vascular risk factors. Understanding the functional properties of EPCs and the factors related to their regenerative capacity will facilitate better use of these progenitor cells in treating vascular disease. Here, we review the current knowledge of EPCs in cerebral neovascularization and tissue regeneration after cerebral ischemia and the factors associated with their regenerative function to better understand the underlying mechanisms and provide more effective strategies for the use of EPCs in treating ischemic stroke.

Automated summary

Endothelial progenitor cells (EPCs) are immature cells capable of proliferating and differentiating into mature endothelial cells (ECs) to repair injured endothelium and form new blood vessels. The regenerative capacity of EPCs is tightly regulated by endogenous and exogenous factors as well as vascular risk factors. Understanding these regulatory mechanisms is crucial for effectively using EPCs in treating vascular diseases like ischemic stroke.